Yifan Bao1, Xiaochao Ma2, Theodore P Rasmussen1, Xiao-Bo Zhong1. 1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, 69 North Eagleville Road, Storrs, CT 06269, USA. 2. Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Abstract
PURPOSE OF THIS REVIEW: In order to combat the development of drug resistance, the clinical treatment of tuberculosis requires the combined use of several anti-tuberculosis (anti-TB) drugs, including isoniazid and rifampicin. Combinational treatment approaches are suggested by the World Health Organization (WHO) and are widely accepted throughout the world. Unfortunately, a major side effect of the treatment is the development of anti-tuberculosis drug-induced liver injury (AT-DILI). Many factors contribute to isoniazid- and rifampicin-mediated AT-DILI and genetic variations are among the most common factors. The purpose of this review is to provide information on genetic variations associated with isoniazid- and rifampicin-mediated AT-DILI. RECENT FINDINGS: The genetic variations associated with AT-DILI have been identified in the genomic regions within or near genes encoding proteins in the following pathways: drug metabolizing enzymes (NAT2, CYP2E1, and GSTs), accumulation of bile acids, lipids, and heme metabolites (CYP7A1, BSEP, UGTs, and PXR), immune adaptation (HLAs and TNF-α), and oxidant challenge (TXNRD1, SOD1, BACH1, and MAFK). SUMMARY: The information summarized in this review considers the genetic bases of risk factors contributing to AT-DILI and provides information that may help for future studies. Some of the implicated genetic variations can be used in the design of genetic tests and serve as biomarkers for the prediction of isoniazid- and rifampicin-mediated AT-DILI risk in personalized medicine.
PURPOSE OF THIS REVIEW: In order to combat the development of drug resistance, the clinical treatment of tuberculosis requires the combined use of several anti-tuberculosis (anti-TB) drugs, including isoniazid and rifampicin. Combinational treatment approaches are suggested by the World Health Organization (WHO) and are widely accepted throughout the world. Unfortunately, a major side effect of the treatment is the development of anti-tuberculosis drug-induced liver injury (AT-DILI). Many factors contribute to isoniazid- and rifampicin-mediated AT-DILI and genetic variations are among the most common factors. The purpose of this review is to provide information on genetic variations associated with isoniazid- and rifampicin-mediated AT-DILI. RECENT FINDINGS: The genetic variations associated with AT-DILI have been identified in the genomic regions within or near genes encoding proteins in the following pathways: drug metabolizing enzymes (NAT2, CYP2E1, and GSTs), accumulation of bile acids, lipids, and heme metabolites (CYP7A1, BSEP, UGTs, and PXR), immune adaptation (HLAs and TNF-α), and oxidant challenge (TXNRD1, SOD1, BACH1, and MAFK). SUMMARY: The information summarized in this review considers the genetic bases of risk factors contributing to AT-DILI and provides information that may help for future studies. Some of the implicated genetic variations can be used in the design of genetic tests and serve as biomarkers for the prediction of isoniazid- and rifampicin-mediated AT-DILI risk in personalized medicine.
Authors: Mohd Amir; Mohammad Ahmed Khan; Sayeed Ahmad; Mohd Akhtar; Mohd Mujeeb; Aftab Ahmad; Shah Alam Khan; Fahad A Al-Abbasi Journal: Nat Prod Res Date: 2015-05-15 Impact factor: 2.861
Authors: Toru Usui; Xiaoli Meng; Katy Saide; John Farrell; Paul Thomson; Paul Whitaker; John Watson; Neil S French; B Kevin Park; Dean J Naisbitt Journal: Toxicol Sci Date: 2016-11-01 Impact factor: 4.849
Authors: Jann Yuan Wang; Ching Hui Tsai; Yungling Leo Lee; Li Na Lee; Chia Lin Hsu; Hsiu Ching Chang; Jong Ming Chen; Cheng An Hsu; Chong Jen Yu; Pan Chyr Yang Journal: Medicine (Baltimore) Date: 2015-06 Impact factor: 1.889
Authors: Kelly S Levano; Luis Jaramillo-Valverde; David D Tarazona; Cesar Sanchez; Silvia Capristano; Tania Vásquez-Loarte; Lely Solari; Alberto Mendoza-Ticona; Alonso Soto; Christian Rojas; Roberto Zegarra-Chapoñan; Heinner Guio Journal: Mol Genet Genomic Med Date: 2021-09-12 Impact factor: 2.183